TOKYO, Mar 31 (Pulse News Wire) – Mrso.,inc (5619.T) reported a revenue decline in fiscal 2025 due to the end of its vaccine business and the completion of large-scale development projects in 2024. The company's revenue was ¥609 million in 2025, down from the previous year.
Despite challenges, MRSO highlighted growth potential through its expanding corporate reservation service, which is expected to drive long-term growth. In the quarter ending March 31, 2026, the company saw a reduction in operating profit to ¥-294 million compared to the previous year. However, MRSO emphasized strategic investments aimed at achieving J-curve growth in 2026.
The firm expects to leverage increased reservations and advertising sales to boost revenue by 17.1% in 2026, reaching ¥725 million. MRSO also noted a stable capital base, maintaining a strong equity ratio of 92.1%. The company remains committed to enhancing its digital health solutions and expanding its presence in the healthcare management sector.
🟡 Confidence: Standard AI-translated content.